Geoffrey Duyk

Dr. Duyk is partner at Circularis Partners, an investment firm focused on supporting technology-enabled companies that advance the circular economy, promote sustainability, and enhance resource efficiency. Prior to Circularis, Dr. Duyk was the managing director and partner of TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology from 2004 to 2017. Prior to joining TPG, Dr. Duyk served on the Board of Directors and was President of Research and Development at Exelixis. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals and served as Vice President of Genomics. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics, and an Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University. He completed his medical and fellowship training at the University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from HHMI. He is a Fellow of the American Association for the Advancement of Science. Dr. Duyk currently serves on the Board of Directors of Anuvia Plant Nutrients; Concentric Ag; and Regen. He is a trustee of Case Western Reserve University where he Chairs the finance committee and is a member of the executive committee and investment committee. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he Chairs the R&D committee. He serves as Chairman of the Board of OncoBay Clinical, a private contract research organization and subsidiary of Moffitt Cancer Center. Dr. Duyk previously served on the Board of Directors of the American Society of Human Genetics (ASHG) where he is currently a member of the organization’s finance committee and Chairs the investment committee. He is a member of the Scientific Advisory Board (SAB) for Lawrence Berkeley National Lab (DOE) and a member of the Advisory Board for Innovatus Capital Partners. Previously, he served as a member of the SAB for Bayer CropSciences, Jackson Labs, as well as numerous NIH advisory committees. Dr. Duyk serves or has served as an advisor (e.g. Qiming Ventures, Grove BioPharma, etc.) or board member to a number of seed stage biotechnology companies.